Chimeric NK receptor and methods for treating cancer

• US 8,252,914 B2
• Filed: 06/08/2011
• Issued: 08/28/2012
• Est. Priority Date: 09/24/2004
• Status: Active Grant

• Current Assignee: The Trustees of Dartmounth College (Dartmouth College)
• Original Assignee: The Trustees of Dartmounth College (Dartmouth College)
• Inventors: Zhang, Tong, Sentman, Charles L.
• Primary Examiner(s): Leffers, Jr., Gerald
• Assistant Examiner(s): SGAGIAS, MAGDALENE K
• Application Number:
  US13/155,909
• Publication Number:
  US 20120029063A1
• Time in Patent Office: 447 Days
• Field of Search: 536/23.1, 435/320.1, 435/325
• US Class Current: 536/23.1
• CPC Class Codes: A61K 2239/31 characterized by the route of administration
• CPC Class Codes: A61K 2239/38 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2239/48 Blood cells, e.g. leukemia or lymphoma
• CPC Class Codes: A61K 35/17 Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes when activated by a specific antigen A61K39/00
• CPC Class Codes: A61K 38/10 Peptides having 12 to 20 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 39/4611 T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
• CPC Class Codes: A61K 39/464429 Molecules with a "CD" designation not provided for elsewhere
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C07K 14/715 for cytokines; for lymphokines; for interferons

Abstract

The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.

Claims

1. A nucleic acid construct for expressing a chimeric polypeptide receptor to reduce or eliminate a tumor comprising:

a first nucleic acid sequence encoding a promoter operably linked to

a second nucleic acid sequence encoding a chimeric polypeptide receptor comprising DAP10 fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif of SEQ ID NO;

1.

2. A vector comprising the nucleic acid construct of claim 1.

3. The nucleic acid construct of claim 1 further comprising a suicide gene.

4. An isolated T cell comprising the nucleic acid construct of claim 1 or claim 3.

5. An isolated T cell comprising the vector of claim 2.